AMGN
Amgen Inc Health Care Biological Products, (No Diagnostic Substances) S&P 500Nasdaq-100Dow 30Russell 3000
$466.01Close
$251.1BMarket cap
$284.12 – $466.0152-week range
Nov 3, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 90 · stronger than 90% of stocks over 12 months
- RS line at a 1-year high outperforming the S&P 500 more than at any point this year
- Near its high at its 52-week high
- Earnings growing EPS +65% year on year, faster than the quarter before (+60 pts)
Cautions
- Extended 4.4 ATR above its 50-day average
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
0%
1wk
up 6.1%
price change
1mo
up 10.6%
price change
12-month return
up 64%
market up 11% ·
its own up 53%
F-score
7 / 9
Strong
Altman Z
2.23
Moderate risk
P/E
32.6×
price / earnings
PEG
0.37
P/E / EPS growth
P/B
29.0×
price / book
Earnings yield
up 3.1%
EBIT / enterprise value
Cheaper than
33%
of the market · expensive
Revenue growth
up 10%
year on year
EPS growth
up 65%
latest quarter · +60 pts
Sales growth
up 10%
latest quarter · +4 pts
ROE
up 106%
return on equity
Free cash margin
up 22%
$8.1B FCF
D/E
5.78
long-term debt / equity
Net debt / EBITDA
2.9×
Interest cover
3.3×EBIT / interest
Piotroski tests
- short-term liquidity weakened
- issued more shares
- profitable on its assets
- generating cash from operations
- profitability improving
- profits backed by cash
- reduced long-term debt
- gross margin widened
- assets working harder
Repair signals
- Long-term debt down 12% ($56.5B → $50.0B)
- Gross margin 61.5% → 67.2%
Trade setup
ATR%
2.5%
$11.48 a day · 2×ATR $443.04
RS
90 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
1.2×
vs 50-day average
Up/down volume
1.18
50 sessions
Implied move
4.8%
by Nov 6, 2026 · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
-
Stage 2 Leader in mixed conditions
- RS 90
- Trend 8/8
- Off 12-month high 0%
- EPS growth +65% (accel +60 pts)
- Sales growth +10% (accel +4 pts)
- Altman Z 2.23 (moderate risk)
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+6% vs market2 sessions after results
Options
$18.7M31.3% IV · activity
Financials
- Gross 67%
- Net 21%
- Free cash 22%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $25.4B | $26.0B | $26.3B | $28.2B | $33.4B | $36.8B |
| Gross margin | 76% | 75% | 76% | 70% | 62% | 67% |
| Operating income | $9.1B | $7.6B | $9.6B | $7.9B | $7.3B | $9.1B |
| Net income | $7.3B | $5.9B | $6.6B | $6.7B | $4.1B | $7.7B |
| Net margin | 29% | 23% | 25% | 24% | 12% | 21% |
| Earnings per share | $12.31 | $10.28 | $12.11 | $12.49 | $7.56 | $14.23 |
| Free cash flow | $9.9B | $8.4B | $8.8B | $7.4B | $10.4B | $8.1B |
| Free cash margin | 39% | 32% | 33% | 26% | 31% | 22% |
| Cash | $6.3B | $8.0B | $7.6B | $10.9B | $12.0B | $9.1B |
| Long-term debt | $32.9B | $33.2B | $37.4B | $63.2B | $56.5B | $50.0B |
| Shareholders' equity | $9.4B | $6.7B | $3.7B | $6.2B | $5.9B | $8.7B |
| Shares outstanding | 578.30m | 558.30m | 534m | 535.40m | 536.90m | 538.80m |
Next report
Nov 3, 2026 · after the close
Expected move The move, either way, the option market prices in through the next scheduled report: the at-the-money straddle for the first expiry that contains it, over the price. It includes the days around the report, so it slightly overstates the report alone. Methodology
±4.8%
$444 – $489 by Nov 6, 2026
Usual move The median, over the company's last four reports, of how far the stock moved either way from the close before the filing to the close of the session after it. Methodology
±6.9%
last 4: +7.6% · -2.4% · +6.2% · +8.0%
Expected against usual The move the options price through this report over the move the last four reports delivered. Above 1 the event is priced bigger than the company's own record; below 1, smaller. A price, not a forecast: it says what protection through the report costs, not which way the stock will go. Methodology
Smaller than usual
0.7× the usual move
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $434 – $500 ±7.1% by Nov 27, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Bigger 31.3% priced · 24.5% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs more
Positioning
- Premium traded
- $18.7M calls $12.6M · puts $6.1M · latest session
- 0.48× +0.16 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +4.43k · puts -1.74k past week
For options traders: ATM IV 31.3% (-2.6% 1w) · 1m ÷ 3m IV 1.06 · 25Δ skew 3.0 pts · Net GEX $41.7M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 1, 2026 | Quarterly ↗ | Mar 31, 2026 | 31d |
| Feb 13, 2026 | Annual ↗ | Dec 31, 2025 | 44d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 2, 2025 | Quarterly ↗ | Mar 31, 2025 | 32d |
| Feb 14, 2025 | Annual ↗ | Dec 31, 2024 | 45d |
| Oct 31, 2024 | Quarterly ↗ | Sep 30, 2024 | 31d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 14, 2024 | Annual ↗ | Dec 31, 2023 | 45d |
| Oct 31, 2023 | Quarterly ↗ | Sep 30, 2023 | 31d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 27, 2026 | Director or officer change ↗ |
| Aug 4, 2026 | Results ↗ |
| Jul 31, 2026 | Cybersecurity incident ↗ |
| May 20, 2026 | Shareholder vote ↗ |
| May 19, 2026 | Director or officer change ↗ |
| Apr 30, 2026 | Results ↗ |
| Apr 22, 2026 | Director or officer change ↗ |
| Feb 19, 2026 | Material agreement ↗ |
| Feb 3, 2026 | Results ↗ |
| Jan 30, 2026 | Agreement ended ↗ |
| Nov 4, 2025 | Results ↗ |
| Aug 5, 2025 | Results ↗ |